Seventure et al. invest £27m in Quanta

Aliad, the venture capital arm of French industrial gas supplier Air Liquide, led the funding round.

Existing backers Wellington Partners, Seroba Kernel, NBGI Ventures, b-to-v Partners and UK engineering company IMI took part in the round. Seventure is a new investor in the company.

Quanta will use the funding to finance clinical introduction and subsequent commercialisation of its SC+ haemodialysis system.

Previous funding
In September 2009, Quanta raised £9m in its series-A round, which was co-led by NBGI, Seroba and Wellington. German firm b-to-v also took part alongside investor network BrainsToVentures.

According to unquote" data, Quanta approached Wellington 18 months prior to the round when it was looking to spin out from IMI.

Company
Founded in 2008 as a spinout from IMI, Alcester-headquartered Quanta develops haemodialysis systems, designed for use in dialysis centres and at home.

Its SC+ product is a portable and compact haemodialysis system. Quanta has developed a cartridge-based design that the company claims allows for greater ease-of-use and treatment flexibility.

According to Quanta, there were 2.3 million dialysis patients worldwide in 2012, and this number is estimated to reach 3.5 million by 2020.

People
John Milad is the CEO of Quanta. The company's board of directors includes NBGI founder and investment director Aris Constantinides, Seroba managing partner Peter Sandys and Wellington partner Rainer Strohmenger.

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• UK / Ireland
• Early-stage
• Healthcare
• United Kingdom
• Seventure (SPEF)
• Wellington Partners
• NBGI Private Equity